Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (178)	12/28/1998 7:31:00 AM
From: jackie	Respond to of 415

John, Enjoyed your posting immensely. I have been waiting several years for the gradual increase in public awareness of this growing threat. It is only a matter of time before one of the 'super' bugs gets loose and starts killing large numbers of people. Say what you will about the man, one thing Clinton has is a very well developed sensitivity to public perceptions. This increase in spending is the result of a combination of increased public concern and an apparent consensus forming in Washington that, if nothing else, mere prudence suggests some more public funding in this area. Several biotech companies stand to benefit from this increased spending and attention. Microcide, ISIS, Xoma, to name a few. Going beyond the hopes of the investors, we should be glad something is finally being done about the growing problem of bacterial resistance to antibiotics. Only question is, is it enough? Regards, Jack Simmons